Kringle 5 (K5) of human plasminogen is a potent angiogenesis inhibitor. In this study, we investigated the effects of recombinant adeno-associated virus (AAV)-mediated delivery of K5 in mouse models of human ovarian cancer. A single intramuscular injection of AAV-K5 resulted in sustained expression of K5 reaching a maximum serum level of 800 ng ml
Introduction
Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies in the United States. In 2007, an estimated 22 430 new cases and 15 280 deaths from this disease were reported. 1 Standard treatment for ovarian cancer is surgery followed by adjuvant chemotherapy using a combination of cis-or carbo platinum and paclitaxel. Despite a higher response rate to the initial therapy, the majority of patients, however, will relapse. As ovarian cancer growth and peritoneal dissemination are angiogenesis dependent, 2, 3 efforts to develop novel therapeutic strategies have redirected the focus from tumor cells to vascular endothelial cells. Targeting endothelial cells, which constitute only a small fraction of the total tumor mass, has been shown to effectively suppress tumor growth and metastasis. [4] [5] [6] [7] About 27 endogenous angiogenesis inhibitors have been thus far characterized. 4 Endogenous angiogenesis inhibitors such as angiostatin, endostatin, and tumstatin, derived from the proteolysis of plasminogen, collagen type XVIII, and collagen IV a3 chain, respectively, can inhibit tumor angiogenesis and growth. [5] [6] [7] Most importantly, antiangiogenic therapy has some additional benefits when compared with conventional chemotherapy. 4, [8] [9] [10] [11] Kringle 5 (K5), a fragment of plasminogen, is a potent endogenous angiogenic inhibitor. In addition to inhibiting endothelial cell proliferation and migration, K5 also induces apoptosis in endothelial cells. [12] [13] [14] [15] [16] [17] A number of earlier studies have shown that tumor growth can be inhibited by systemically administering recombinant K5 (rK5) to mice. 14, [18] [19] [20] [21] Efficacy of angiogenesis inhibitors is, however, affected by the dosing and schedule. For example, endostatin treatment of tumor-bearing mice showed a bell-shaped dose response. 22 Efficacy of endostatin was again improved by fractional dosing (twice daily) and slow-release formulations. [23] [24] [25] Therefore, success of antiangiogenic treatment depends on maintaining optimal levels of the inhibitor in circulation for a prolonged period. Gene therapy seems to be ideal to achieve these goals. Earlier studies have shown that intramuscular administration adeno-associated virus (AAV)-based gene therapy provides long term (for 41.5 years) 26, 27 and sustained delivery of angiogenesis inhibitors. 28, 29 In addition, AAV-based gene therapy can transduce a broad range of host cells without evoking a strong immune response. 25, 30 Using this system, we determined the effects of AAV-K5 gene therapy on ovarian cancer growth in a clinically relevant mouse model. The results show that a single dose of AAV-K5 led to sustained expression of K5 and improved the survival of treated mice by inhibiting tumor angiogenesis.
Results

Effect of AAV-K5 on angiogenesis
Initially, we investigated whether rK5 secreted by AAV-K5 infected HEK-293 cells was capable of inhibiting endothelial cells in vitro. These studies showed that rK5 inhibited vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, migration, and tube formation. In addition, rK5 also induced endothelial cell death in a concentration-dependent manner. 13 On the basis of these findings, we investigated whether AAVmediated delivery of K5 could be therapeutically useful in preclinical models. Groups of athymic nude mice were injected with different doses of AAV-K5 viral particles (v.p.). Eight weeks after the virus administration, mice were subcutaneously (s.c.) injected with matrigel preparations containing either human VEGF165 or MA148 cells, a human epithelial ovarian carcinoma cell line. After 1 week, implants were resected to determine vessel density and architecture. 31 Serum samples obtained from mice at the time of sacrifice were also used to determine the circulating levels of rK5. Figure 1a shows a dosedependent increase in serum rK5 levels, which is positively correlated with the number of viral particles (Po0.0005). Serum samples from mice injected with a control AAV vector were used as controls to determine the basal levels of K5. Intramuscular (i.m.) injection of a 5 Â 10 8 v.p. showed a mean serum levels of 21 ng ml
À1
. At 5 Â 10 9 v.p., the circulating levels of rK5 reached 800 ng ml
. Frozen sections of matrigel plugs obtained from the treated mice were then analyzed for vessel density. 31 Data in Figures 1b-d show relative angiogenesis of matrigel plugs. Both growth factor-induced and tumor cell-induced angiogenesis were inhibited by AAV-K5 treatment. Morphometric analysis of CD31-positive vessels showed a negative correlation between the serum rK5 levels and the reduction of vessel length, ends, and nodes (Po0.005, Po0.01, Po0.005, respectively) in AAV-K5-treated mice when compared with control groups (Figures 1b-d) . Collectively, these data suggest that AAV-mediated expression of rK5 inhibits neovascularization. On the basis of these findings, a dose of 5 Â 10 9 -AAV-K5 v.p. was selected to further study the effects of K5 on ovarian cancer growth in mouse.
Effects of AAV-K5 gene therapy on ovarian cancer growth
To investigate the potential of AAV-K5-mediated gene therapy, female athymic mice were transplanted with an ovarian cancer cell line, MA148 (2 Â 10 6 ) subcutaneously (s.c.). In this model, palpable tumors were detected by 3 weeks after the tumor cell implantation. 29 Earlier studies from our laboratories have established that AAV-based gene therapy results in approximately a 3-week delay in trans-gene expression of endostatin, an angiogenesis inhibitor derived from collagen type XVIII. 28, 29 In addition, matrigel plug assays also indicated that plasma rK5 levels were elevated during this time frame. Therefore, gene therapy was initiated on day 2 following tumor cell injections. Data in Figure 2a show the relative growth rate of ovarian cancer in AAV-GFP and AAV-K5-injected mice. The control group developed palpable Different doses of AAV-K5 viral particles were injected into mice i.m. Matrigel plugs were implanted s.c. after 8 weeks. One week after the implantation, blood samples were collected from mice to determine the rK5 levels in circulation. rK5 levels in the serum of AAV-K5-treated mice (') and AAV-GFP-treated mice (&) were determined by ELISA. Inhibition of VEGF/tumor-induced angiogenesis in vivo. Matrigel plug sections were stained with rat anti-mouse CD31-phycoerythrin (PE) conjugate. Images acquired from these studies were quantified for vessel density by a previously published method. 31 AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al tumors 28 days after tumor cell implantation that reached an average size of 800 mm 3 by day 42. In contrast, AAV-K5 gene therapy caused a significant reduction in tumor growth (Figures 2a and b) . AAV-GFP-injected mice (n ¼ 5) with larger, ulcerated tumors were euthanized on day 42. AAV-K5-treated mice showed a reduced tumor volume at this time point (mean value B391 mm 3 ). Representative animals (n ¼ 5) were also sacrificed from the experimental arm for comparison. Remaining mice were followed for additional 1 week. At the time of sacrifice, the control group showed a mean tumor volume of 1500 mm 3 when compared with the AAV-K5-injected mice, which had a mean tumor volume of 500 mm 3 (Po0.001). Tumors resected at the time killing on day 49 showed a 40% reduction in wet weight in the AAV-K5-treated mice.
To further investigate whether inhibition of tumor growth is in fact mediated by reduced angiogenesis, tumors from both control and treated animals were analyzed for vessel density using morphometric methods. Representative images of CD31-positive blood vessels from the frozen sections (day 42) are shown in Figure 3a . These studies showed a reduction in the number of vessel ends, nodes, and length (Figures 3b-d ) in rAAV-K5-treated mice when compared with control animals. On day 42, the number of vessel ends was reduced by 22% ( Figure 3b) ; branch points of vessels, which are represented as nodes (Figure 3c ), were reduced by 37% in AAV-K5-treated group. Total vessel length per field was reduced by 45% when compared with the control group treated with AAV-GFP. Similarly, tumor tissues obtained on day 49 also showed significant inhibition of vessel nodes and length. Vessel ends, however, did not show significant reduction in the AAV-K5-treatment group. Histopathology of normal tissues such as muscle (v.p. injection site), kidney, and liver did not show any gross histological changes in either of the groups of animals. Tumor tissues from AAV-K5-treated mice, however, showed necrosis and decreased cell density ( Figure 3e ).
Inhibition of orthotopic ovarian cancer growth in mice
We have previously described an orthotopic model of epithelial ovarian cancer using DsRed2-labeled MA148 cells that allowed us to non-invasively monitor tumor growth. 28 AAV-K5 gene therapy was initiated 2 days after intraperitoneal injection of tumor cells. Figure 4a shows representative images of a control and AAV-K5-treated mice. Control mice treated with AAV-GFP showed rapid progression and by day 72 the peritoneum was completely filled with tumor tissue. Tumor nodules were also noticed in the ovaries and uterine tissues. In contrast, the AAV-K5-treated mice showed slower progression, and the cumulative tumor burden was lesser even on day 185. Inhibition of tumor growth correlated with secretion of K5 into the systemic circulation. Figure 4b shows the serum levels of K5. Detectable levels of K5 were seen as early as day 14 . Peak values of about 600 ng ml À1 K5 was observed on day 63 following which the levels reduced to 325 ng ml À1 by day 80. Sera from GFP-treated control mice showed basal levels of K5. Survival data are shown in Figure 4c . Control mice showed a median survival time of 63 days, and all mice died by day 72. In comparison, gene therapy with AAV-K5 resulted in the long-term survival of 40% of the mice. All the surviving mice were euthanized on day 185. The residual tumor tissues of both treated and control groups were removed and weighed. Figure 4e shows the tumor burden from control (AAV-GFP) and AAV-K5-treated animals at the time of sacrifice. Tumor weight from individual mouse is shown in the histogram. One of the control group of animals were euthanized on day 56, and the rest of the five mice were sacrificed on day 72, as they became moribund due to tumor burden. In contrast, the K5-treated mice showed reduced tumor growth. AAV-K5 gene therapy reduced 9 v.p.) ('). Tumor growth was determined by weekly measurement using a caliper. Five mice were sacrificed on day 42, and the remaining five animals were euthanized on day 49. Arrows denote the time of killing. (b) Tumor burden at necropsy from AAV-K5-treated mice (') and control-AAV-GFP-treated mice (&) determined at day 42 (*Po0.05) and day 49 after v.p. injection (**Po0.001). GFP-treated mice (n ¼ 5) with large, ulcerated tumors were euthanized at day 42. An equal number of AAV-K5-treated mice that shows palpable tumors (n ¼ 5) were also sacrificed on day 42. Columns, mean; bars, s.e.; asterisk, statistical significance.
AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al the cumulative tumor burden by 60.0% (P ¼ 0.0011). Statistical Student's t-test analysis further indicated that AAV-K5 treatment confers survival advantage to athymic mice orthotopically transplanted with ovarian cancer. As a preliminary investigation, we determined the creatinine levels to assess renal function in control and treated mice. Results in Figure 4d show negligible difference in serum creatinine levels between the control and treated mice on day 14. However, a slight increase in creatinine levels was observed in the AAV-GFP-treated group at the time of killing (0.567 ± 0.014 mg per 100 ml) (Po0.001), which was statistically significant. AAV-K5-treated animals did not show any significant change in the serum creatinine levels when compared with the control group.
These studies suggest that AAV-K5 gene therapy did not significantly alter the renal function.
Inhibition of tumor neovascularization
We further wanted to address the influence of K5 treatment on the tumor-associated vasculatures, specifically, vessel density and vessel normalization. Morphometric analysis of vessel density indicated significant reduction in tumor-associated vessels in tumor tissues resected from AAV-K5-treated mice. The number of vessel ends, vessel nodes, and vessel length were reduced by 50, 72, and 50% (Po0.001), respectively, when compared with those of AAV-GFP-treated control animals (Figures 5a-c) . To understand whether the AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al Figure 4 The antiangiogenic gene therapy with K5 in an orthotopic model of epithelial ovarian cancer. (a) Exponentially growing DsRedexpressing-MA148 cells (2 Â 10 6 ) in 500 ml serum-free media suspension were injected intraperitoneally into 6-8weeks old, female, athymic nude mice. After 2 days, mice were injected i.m. with either AAV-GFP (5 Â 10 9 , 100 ml) (n ¼ 10) or AAV-K5 (5 Â 10 9 , 100 ml) (n ¼ 10). Representative images of the treated and the control mice were taken at the indicated time points after either AAV-K5 (rows 1 and 2) or AAV-GFP v.p. injection (rows 3 and 4). In addition, images of the ovaries and the uterine horns of AAV-GFP-treated mouse (yellow arrow head) and those of AAV-K5 were captured on day 72. Mice were imaged using a Leica dissection microscope under bright field and under the green filter (excitation, 546/10 nm; dichroic, 565 LP; emission, 590 LP). The digital images were acquired by a Nikon camera. Scale bar, 3 cm. AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al antiangiogenic gene therapy affected both nascent and mature blood vessels, tumor sections were stained with both anti-CD31-PE and anti-a-smooth muscle actin-FITC, a marker for pericytes and vascular smooth muscle cells of mature vasculature. 28, [32] [33] [34] Representative images (Figure 5d ) of the overlapping areas of blood vessels and pericyte-coated vessels were recorded and differentially quantified. 28, 31 Figure 5e summarizes the effect of AAV-K5 treatment on immature vasculature. Approximately 70% of blood vessels in tumors resected from AAV-GFP-treated mice were devoid of pericytes. Lack of a-SMA staining suggests that most of the vessels are newly formed and immature.
28,32-34 AAV-K5-treated mice showed a lower number of CD31-positive vessels per section. However, most of the remaining vasculatures (70% of the total) in AAV-K5-treated mice were positive for a-SMA. The data suggest that AAV-K5 gene therapy preferentially eliminated newly formed and immature blood vessels. To further validate this finding, tumor sections were analyzed for vessels covered with cells positive for PDGFR-b. PDGFR-b is a validated marker for perivascular progenitors and immature pericytes. Upon differentiation, PDGFR-b expression is inhibited. 35 Therefore, we determined the levels of PDGFR-b in cells associated with CD31-positive endothelium. Co-localization studies showed a reduction in the number of vessels positive for PDGFR-b. PDGFRmediated signaling leads to vessel normalization and reduced vessel leakage. [32] [33] [34] [35] Figure 5f shows representative images of PDGFR-b staining of tumor sections. AAV-K5 treatment significantly reduced vessels covered with PDGFR-b positive cells by up to 60% (Figure 5g ). Tumor sections from AAV-GFP-treated mice showed about 52% of the vessels positive for PDGFR-b. Only 19% of the Inhibition of angiogenesis is expected to affect the tumor cell survival. As an indication of changes in tumor burden and cell viability, serum levels of human VEGF were determined in the control and AAV-K5-treated mice. As shown in Figure 5h , the control group had a mean human VEGF level of 279 ng ml À1 in the serum at the time of killing. Recombinant AAV-K5-treated animals had a mean serum VEGF level of 150 ng ml À1 (P ¼ 0.03). Collectively, these data support that AAV-K5 gene therapy is effective in inhibiting tumor angiogenesis in orthotopic growth of ovarian cancer and as a consequence, confers significant survival advantage.
Discussion
A number of studies have shown that angiogenesis inhibitors are more effective when given in fractional doses or in slow-release formulations to attain sustained levels in the serum. 23, 25 Unlike protein-based therapeutics, gene therapy approach overcome many of the obstacles in achieving sustained systemic levels of antiangiogenic molecules. Both viral and non-viral vectors are used for transgenic expression of angiogenesis inhibitors. Non-viral vectors have been encapsulated into cationic liposomes to improve basal transduction frequencies. 36 These studies have shown that hepatocellular carcinoma was effectively inhibited by K 1-4 of plasminogen (angiostatin). Other investigators have used electroporation of plasmid DNA encoding K5 of plasminogen to inhibit LLC in mice. 20 Among the viral vectors, adenovirus was effective to transiently express kringle domains 1-4 of hepatocyte growth factor (NK4) in mice.
37 NK4 inhibited the growth of pancreatic cancer cells. Although gene therapy alone was successful in inhibiting tumor growth, additional therapeutic benefit was observed when the antiangiogenic molecule was expressed in a replication competent virus construct. Oncolytic adenovirus construct of a mutant K5 (mutation to reduce lysine binding, L71R) was more potent in inhibiting colorectal tumors in mice. 38 Adenoviral constructs, however, require multiple injections to maintain significant serum levels of the inhibitor and furthermore, immune response to adenovirus limits repeated administration. This problem can be overcome by using AAV. Indeed, the first kringle domain of HGF (HGFK1) was successfully used to treat hepatocellular carcinoma in mice. 39 In the present studies, we show that AAVmediated gene therapy of K5 of plasminogen inhibits angiogenesis efficiently. A single intramuscular injection of AAV-K5 produced significant amounts of K5 in circulation in a dose-dependent manner. At the highest virus dose tested (5 Â 10 9 ), the serum levels of K5 reached about 800 ng ml À1 , which is significantly higher than the levels observed in AAV-endostatin treatment. In these studies, serum levels varied between 24 and 170 ng ml À1 . 29, 40 Higher levels of K5 in the serum could have resulted from a combination factor influenced by the differences in the pharmacokinetics, efficiency of integration, and translational capacity.
After establishing that the AAV-K5 gene therapy inhibited angiogenesis in matrigel plug assays, we investigated the effect of K5 on ovarian cancer growth in athymic mice. In the first series of experiments, the ability of K5 to inhibit subcutaneous growth of ovarian cancer was determined. Gene therapy resulted in K5 expression reaching peak levels on day 63, which is in agreement with other studies wherein stable protein expression was observed during week 8 to 26.
41 AAV-K5 treatment prolonged the survival of mice without toxicity as judged by the body weight gain and kidney function as assessed by serum creatinine levels, which measures the glomerular filtration rate. A systematic evaluation of acute and chronic toxicity studies needs to be performed before clinical development of AAV-K5 gene therapy. Gene therapy significantly reduced the residual tumor weight when compared with the control groups. Reduced tumor burden correlated with the inhibition of tumor neovascularization. Most importantly, AAV-mediated K5 gene therapy not only inhibited subcutaneous tumor growth but also the intraperitoneal growth of ovarian cancer. As the orthotopic microenvironment is different than the subcutaneous site, inhibition of ovarian cancer growth in the peritoneum is highly relevant.
Our studies are in agreement with an earlier study using an orthotopic model of retrovirally engineered glioma cells secreting rK5, which showed reduced angiogenesis leading to a delay in tumor growth and prolonged survival. 14 In this model system, tumor cells secreted angiogenesis inhibitor directly into the tumor microenvironment. Present studies used i.m. injection to transducer skeletal myocytes to secrete K5 into the circulation. Furthermore, we evaluated the effect of systemically secreted K5 on tumors growing at distant sites such as s.c. and peritoneum. AAV-K5 reduced vessel density and tumor burden in this clinically relevant model, which resulted in increased survival. The manner in which reduced angiogenesis indirectly affected the viability of tumor cells is evident by the increase in the number of apoptotic cells in AAV-K5-treated tumors. Consequently, serum levels of human VEGF decreased in AAV-K5-treated animals reflecting reduced tumor burden. Recombinant AAV-K5 gene therapy also differentially affected the nascent vessels more than the mature vasculature, which is reflected by the disproportionate number of a-smooth muscle positive pericytecoated vasculatures in AAV-K5-treated tumors. In addition, AAV-K5 treatment reduced vessels covered with PDGFR-b positive immature pericytes confirming the former observation. Similar differential effect on nascent vasculature was also observed in other studies using antiangiogenic molecules such as endostatin, avastin, and anginex. 28, [42] [43] [44] [45] [46] PDGF-mediated signaling is important for tumor angiogenesis and vessel maturity. In an interesting recent publication, Greenberg et al. 47 showed that VEGF may AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al antagonize PDGF signaling thereby increasing the number of immature vessels in tumors. Present studies show decreased serum levels of VEGF in AAV-K5-treated mice. Reduced VEGF levels can also increase PDGFinduced recruitment of pericytes. Recent studies suggest that PDGF-BB and PDGF-AB along with FGF-2 are necessary and sufficient to produce mature vasculature. 48 Furthermore, PDGF-C secreted by tumor-associated fibroblasts (stromal cells) can compensate for VEGF and maintain a pro-angiogenic environment when VEGF is neutralized by antibodies. Although, we have not determined the effects of AAV-K5 gene therapy on tumor stroma, changes in stromal cells can profoundly affect tumor growth and sensitivity to chemotherapy. Using a transgenic mouse model of pancreatic ductal carcinoma, Olive et al. 49 have found that elimination of stromal cells by an inhibitor of Hedgehog signaling pathway actually improved sensitivity to gemcitabine. We intent to study the effect of AAV-K5 on tumor stroma in the future and determine changes in chemosensitivity following AAV-K5 treatment. Current studies indicated that rAAV-K5 treatment substantially reduced tumor vascularity validating the in vitro studies showing rK5 targets proliferating endothelial cells and has minimal inhibitory effects on confluent human umbilical vein endothelial cells (HUVECs) population (data not shown). The effect of rK5 on VEGF receptors is also hitherto unknown, 21 nevertheless, it is noteworthy that VEGF can rescue some of the effect of rK5 on endothelial cells. For example, K5-induced autophagy was partially reversed by VEGF. 13 Therefore, it is likely that K5-mediated signaling overlaps with VEGFR-mediated intracellular signaling pathway at some point.
Successful inhibition of sprouting blood vessels deprives tumors from essential nutrients and oxygen. 45, 50 Tumors, however, can evade such insults by switching over to other redundant mechanisms to sustain angiogenesis. 51 For example, VEGF-null mouse fibrosarcoma cells were able to induce angiogenesis by secreting PDGF that stimulated the stromal fibroblasts by a paracrine mechanism to activate VEGF secretion into tumor microenvironment. 52 Therefore, it is not only important to block VEGF secreted by the tumor cells but also interfere with alternate paracrine mechanisms that may contribute to tumor angiogenesis. This notion is further reiterated by a recent study wherein tumor-associated fibroblasts that are unresponsive to anti-VEGF therapy seem to use PDGF-C-induced angiogenic pathways to survive. 53 These studies further emphasize the need for alternate antiangiogenic therapies. K5 treatment can be useful in overcoming some of the limitations seen in VEGF inhibitors. Earlier studies have suggested that the combination between chemotherapy and antiangiogenic therapy can improve survival of the treated animals. 28, 45 It is not known whether the combination of AAV-K5 and chemotherapy may improve the therapeutic outcome.
In conclusion, we have shown that a single injection of AAV-K5 resulted in sustained levels of rK5 in serum. Maintaining an antiangiogenic pressure is important for the successful elimination of tumors. For example, shortterm treatment with VEGFR and PDGFR kinase inhibitors actually accelerated tumor growth and metastasis in experimental model systems. 54 Therefore, gene therapy approach will have a better chance in enforcing an antiangiogenic microenvironment for prolonged periods of time. Recombinant AAV-K5 treatment significantly inhibited tumor growth and angiogenesis in a clinically relevant ovarian cancer model. Although AAV-K5 monotherapy was shown to induce a high percentage of vessel normalization, the use of multiple maintenance doses of AAV-K5 may provide better efficacy when combined with radiation or chemotherapy to synergistically inhibit ovarian cancer.
Materials and methods
Materials
Recombinant hVEGF (VEGF165) was obtained from R&D systems (Minneapolis, MN, USA). PE-conjugated monoclonal antibody to mouse CD31 was from Pharmingen (San Diego, CA, USA). A monoclonal anti-His (C-term) antibody was bought from Invitrogen (San Diego, CA, USA). a-smooth muscle actin-FITC was from Sigma Chemical (St Louis, MO, USA). Creatinine assay kit and rabbit monoclonal antibody to PDGFR-b were obtained from Abcam Inc. (Cambridge, MA, USA).
Cell culture
We have previously described the characteristics of a human epithelial ovarian cancer cell line stably expressing DsRed. 
Vector construction and protein purification
Preparation and titration of AAV-K5 and AAV-GFP using helper-free AAV-2 virus (Stratagene) have been described earlier.
17 rK5 was purified and characterized as described earlier. 17, 29 Purified rK5 was used as a standard in a sandwich ELISA to detect serum levels of K5 in mice. A monoclonal anti-His (C-term) antibody (Invitrogen) was used to capture rK5 and a goat polyclonal antibodies to human plasminogen (Abcam Inc.) was used to develop concentration-dependent signal in a sandwich ELISA.
Matrigel plug neovascularization assay
Athymic nude mice (National Cancer Institute, Bethesda, MD, USA) (n ¼ 6-12) were injected intramuscularly (i.m.) with AAV-K5 (5 Â 10 8 , 1 Â 10 9 , 2.5 Â 10 9 , 5 Â 10 9 v.p.) or AAV-GFP (n ¼ 10) (5 Â 10 9 v.p.). After 8 weeks, mice were implanted s.c. with 500 ml of matrigel preparations containing either 200 ng ml À1 of rhVEGF and 20 units ml À1 of heparin (Sigma) or 2 Â 10 6 MA148 cells ml
À1
. Matrigel plugs were surgically removed 7 days after implantation. Microvessel density was evaluated by immunofluorescence method using rat anti-mouse-CD31-PE conjugate as described earlier. 31 
Animal studies
Exponentially growing MA148 ovarian cancer cells or DsRed-expressing-MA148 cells were harvested by trypsinization and resuspended in serum-free RPMI 1640. Cells (2 Â 10 6 ) were injected subcutaneously into the flanks of 6-8 weeks old, female, athymic nude mice. Orthotopic model used intraperitoneal injection of a AAV-mediated delivery of K5 of human plasminogen and ovarian cancer TMB Nguyen et al suspension of DsRed-expressing-MA148 cells. After 2 days, mice were injected i.m. with either AAV-GFP (5 Â 10 9 , 100 ml) (n ¼ 10) or AAV-K5 (5 Â 10 9 , 100 ml) (n ¼ 10). Tumor growth was monitored by imaging (i.p.) 28 or by caliper measurement (s.c.). 29 Animals were sacrificed when the tumor volume reached about 1000 mm 3 or ulcerated with an open wound. Serum samples were collected at different time points to assay for hVEGF levels in circulation by ELISA (R&D Systems).
Vessel staining and histopathological studies
Immunofluorescence studies were performed as described earlier. 31 Briefly, frozen sections were acetone fixed and labeled with either a PE-conjugated monoclonal antibody to mouse CD31 and an anti-mouse a-smooth muscle actin-FITC or a rabbit monoclonal PDGFR-b. DAPI was used to label nuclei. Images were recorded by an Olympus BX-60 fluorescence microscope at 200 Â magnification. Digital images were further processed as described earlier to analyze for vessel architecture and characteristics using Metamorph Image Analysis Software (Image 1, Westchester, PA, USA), the Image Processing Toolkit (RGI Inc., Raleigh, NC, USA) and Adobe Photoshop (Adobe Inc., Mountain View, CA, USA). Tissue samples of tumor, liver, muscle from the injection site, and kidney were processed for H&E staining. Statistical significance was calculated by the Student's t-test.
